Share Price and Basic Stock Data
Last Updated: February 12, 2026, 8:56 pm
| PEG Ratio | 11.19 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Jubilant Pharmova Ltd, a prominent player in the pharmaceuticals sector, reported a current market price of ₹938 with a market capitalization of ₹14,948 Cr. The company’s sales have shown a steady upward trajectory, with quarterly revenue rising from ₹1,600 Cr in September 2022 to ₹1,680 Cr in September 2023. This growth reflects a consistent demand for its products and an effective operational strategy. Over the past fiscal years, total sales increased from ₹6,130 Cr in FY 2022 to ₹6,282 Cr in FY 2023, and are projected to reach ₹7,234 Cr in FY 2025. The operating profit margin (OPM) stood at 17% in the latest reporting, indicating a healthy operational efficiency. The company’s approach to maintaining and expanding its product portfolio, coupled with strategic market positioning, has enabled it to capitalize on growth opportunities in the pharmaceutical landscape, which is characterized by increasing healthcare demands and innovation. Overall, Jubilant’s sales performance aligns well with the growth trends observed in the broader pharmaceutical industry, which has been buoyed by rising healthcare expenditure across India.
Profitability and Efficiency Metrics
Jubilant Pharmova’s profitability metrics demonstrate a mixed performance, with a net profit of ₹474 Cr and a return on equity (ROE) of 9.55%. The company’s operating profit margin (OPM) is commendable at 17%, indicating sound operational management. However, fluctuations in net profit have been noted, particularly with a significant dip in FY 2023, where it recorded a loss of ₹65 Cr. The interest coverage ratio (ICR) stood at a robust 5.12x, suggesting that the company can comfortably meet its interest obligations. However, the return on capital employed (ROCE) has room for improvement, recorded at 9.54%, which is relatively low compared to typical sector benchmarks. The cash conversion cycle (CCC) of 65 days indicates efficient management of working capital, although this could be optimized further to enhance liquidity. Overall, while Jubilant Pharmova showcases strengths in operational efficiency and interest coverage, its profitability metrics highlight areas for improvement in sustaining consistent net income growth.
Balance Sheet Strength and Financial Ratios
Jubilant Pharmova’s balance sheet reflects a solid financial foundation, with total assets amounting to ₹12,584 Cr as of FY 2025. The company reported reserves of ₹6,576 Cr, which are vital for future growth and stability. The total borrowings recorded at ₹2,883 Cr indicate a manageable debt level, with a total debt-to-equity ratio of 0.38x, suggesting prudent leverage practices. The price-to-book value (P/BV) ratio stood at 2.25x, which aligns with industry averages, reflecting investor confidence in the company’s asset base. The current ratio is a healthy 1.65, indicating good short-term financial health. Moreover, the company has demonstrated a consistent ability to retain earnings, as highlighted by an earnings retention ratio of 90.52%. Overall, Jubilant Pharmova’s balance sheet indicates a well-capitalized entity with adequate liquidity and leverage, positioning it to navigate potential market challenges effectively.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Jubilant Pharmova indicates a diverse ownership structure, with promoters holding 47.67% of the equity as of September 2025, down from 50.67% in earlier quarters. This decline may reflect a strategic move to increase liquidity or attract institutional investors. Foreign institutional investors (FIIs) hold 16.56%, while domestic institutional investors (DIIs) have increased their stake to 10.53%. The public shareholding stands at 24.60%, demonstrating a balanced distribution of ownership. The total number of shareholders has decreased from 1,00,212 in December 2022 to 93,336 in September 2025, suggesting some consolidation among investors. This mixed ownership structure, with substantial institutional backing, is a positive indicator of investor confidence. However, the reduction in promoter holding may raise questions about the long-term strategic vision. Overall, the diverse investor base reflects a stable outlook for the company, although close monitoring of shareholding changes is warranted.
Outlook, Risks, and Final Insight
Jubilant Pharmova is well-positioned to capitalize on growth opportunities within the pharmaceutical sector, driven by increasing healthcare needs and a robust product pipeline. However, the company faces risks such as fluctuating profitability, as evidenced by recent net losses, and potential regulatory challenges that could impact operational efficiency. Furthermore, while the interest coverage ratio is healthy, any significant increase in borrowing could affect financial stability. The company’s ability to sustain growth in sales and profitability will depend on its strategic initiatives and market conditions. Investors should consider both the strengths, such as solid balance sheet metrics and operational efficiency, and risks like profitability volatility and shareholding shifts. In scenarios where the company successfully navigates these challenges, it could enhance shareholder value significantly; conversely, failure to address profitability concerns may hamper growth and investor confidence.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 133 Cr. | 106 | 158/84.3 | 29.4 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.21 Cr. | 1.68 | 4.15/1.68 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 3,451 Cr. | 319 | 479/192 | 72.2 | 24.3 | 0.21 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 30.6 Cr. | 41.3 | 79.8/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 82.8 Cr. | 56.5 | 56.7/17.0 | 197 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 19,994.39 Cr | 1,109.18 | 54.25 | 201.93 | 0.36% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,600 | 1,552 | 1,678 | 1,587 | 1,680 | 1,677 | 1,759 | 1,732 | 1,752 | 1,822 | 1,929 | 1,901 | 1,966 |
| Expenses | 1,384 | 1,408 | 1,459 | 1,419 | 1,438 | 1,459 | 1,487 | 1,480 | 1,463 | 1,535 | 1,584 | 1,611 | 1,625 |
| Operating Profit | 216 | 144 | 219 | 168 | 242 | 218 | 271 | 252 | 289 | 287 | 345 | 290 | 341 |
| OPM % | 14% | 9% | 13% | 11% | 14% | 13% | 15% | 15% | 17% | 16% | 18% | 15% | 17% |
| Other Income | -44 | 10 | 21 | 9 | 19 | 49 | -151 | 410 | 8 | -10 | 9 | 12 | 4 |
| Interest | 42 | 51 | 56 | 62 | 66 | 71 | 73 | 71 | 61 | 56 | 53 | 49 | 50 |
| Depreciation | 94 | 94 | 271 | 90 | 97 | 95 | 101 | 91 | 91 | 91 | 95 | 98 | 105 |
| Profit before tax | 36 | 9 | -86 | 25 | 98 | 101 | -54 | 500 | 144 | 130 | 206 | 154 | 190 |
| Tax % | 87% | 285% | 16% | 76% | 37% | 34% | 15% | 4% | 29% | 23% | 27% | 34% | 37% |
| Net Profit | 5 | -16 | -100 | 6 | 62 | 66 | -62 | 482 | 102 | 101 | 151 | 102 | 120 |
| EPS in Rs | 0.34 | -0.98 | -6.15 | 0.40 | 3.92 | 4.19 | -3.68 | 30.26 | 6.45 | 6.33 | 9.64 | 6.46 | 7.55 |
Last Updated: December 30, 2025, 8:33 am
Below is a detailed analysis of the quarterly data for Jubilant Pharmova Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 1,966.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,901.00 Cr. (Jun 2025) to 1,966.00 Cr., marking an increase of 65.00 Cr..
- For Expenses, as of Sep 2025, the value is 1,625.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,611.00 Cr. (Jun 2025) to 1,625.00 Cr., marking an increase of 14.00 Cr..
- For Operating Profit, as of Sep 2025, the value is 341.00 Cr.. The value appears strong and on an upward trend. It has increased from 290.00 Cr. (Jun 2025) to 341.00 Cr., marking an increase of 51.00 Cr..
- For OPM %, as of Sep 2025, the value is 17.00%. The value appears strong and on an upward trend. It has increased from 15.00% (Jun 2025) to 17.00%, marking an increase of 2.00%.
- For Other Income, as of Sep 2025, the value is 4.00 Cr.. The value appears to be declining and may need further review. It has decreased from 12.00 Cr. (Jun 2025) to 4.00 Cr., marking a decrease of 8.00 Cr..
- For Interest, as of Sep 2025, the value is 50.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 49.00 Cr. (Jun 2025) to 50.00 Cr., marking an increase of 1.00 Cr..
- For Depreciation, as of Sep 2025, the value is 105.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 98.00 Cr. (Jun 2025) to 105.00 Cr., marking an increase of 7.00 Cr..
- For Profit before tax, as of Sep 2025, the value is 190.00 Cr.. The value appears strong and on an upward trend. It has increased from 154.00 Cr. (Jun 2025) to 190.00 Cr., marking an increase of 36.00 Cr..
- For Tax %, as of Sep 2025, the value is 37.00%. The value appears to be increasing, which may not be favorable. It has increased from 34.00% (Jun 2025) to 37.00%, marking an increase of 3.00%.
- For Net Profit, as of Sep 2025, the value is 120.00 Cr.. The value appears strong and on an upward trend. It has increased from 102.00 Cr. (Jun 2025) to 120.00 Cr., marking an increase of 18.00 Cr..
- For EPS in Rs, as of Sep 2025, the value is 7.55. The value appears strong and on an upward trend. It has increased from 6.46 (Jun 2025) to 7.55, marking an increase of 1.09.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 5:07 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 5,762 | 5,751 | 5,749 | 5,861 | 7,518 | 9,111 | 5,976 | 6,099 | 6,130 | 6,282 | 6,703 | 7,234 | 7,618 |
| Expenses | 4,763 | 5,141 | 4,493 | 4,510 | 5,995 | 7,367 | 4,428 | 4,695 | 4,980 | 5,503 | 5,802 | 6,061 | 6,354 |
| Operating Profit | 999 | 610 | 1,256 | 1,352 | 1,522 | 1,744 | 1,548 | 1,403 | 1,150 | 779 | 901 | 1,173 | 1,263 |
| OPM % | 17% | 11% | 22% | 23% | 20% | 19% | 26% | 23% | 19% | 12% | 13% | 16% | 17% |
| Other Income | -173 | 86 | 4 | 19 | 36 | -249 | 225 | 263 | 8 | -9 | -76 | 416 | 15 |
| Interest | 337 | 368 | 371 | 341 | 284 | 220 | 200 | 184 | 145 | 188 | 272 | 240 | 208 |
| Depreciation | 281 | 288 | 347 | 291 | 415 | 371 | 340 | 349 | 382 | 554 | 382 | 369 | 389 |
| Profit before tax | 207 | 40 | 542 | 738 | 859 | 904 | 1,233 | 1,133 | 630 | 28 | 170 | 981 | 681 |
| Tax % | 34% | 200% | 29% | 22% | 26% | 36% | 27% | 26% | 34% | 333% | 57% | 15% | |
| Net Profit | 138 | -40 | 387 | 575 | 634 | 577 | 898 | 836 | 413 | -65 | 73 | 836 | 474 |
| EPS in Rs | 6.84 | -3.63 | 24.60 | 36.14 | 40.35 | 36.06 | 56.39 | 52.47 | 25.98 | -3.83 | 4.84 | 52.69 | 29.98 |
| Dividend Payout % | 43% | -83% | 12% | 8% | 7% | 12% | 9% | 10% | 19% | -130% | 102% | 9% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -128.99% | 1067.50% | 48.58% | 10.26% | -8.99% | 55.63% | -6.90% | -50.60% | -115.74% | 212.31% | 1045.21% |
| Change in YoY Net Profit Growth (%) | 0.00% | 1196.49% | -1018.92% | -38.32% | -19.25% | 64.62% | -62.54% | -43.69% | -65.14% | 328.05% | 832.90% |
Jubilant Pharmova Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 2% |
| 5 Years: | 4% |
| 3 Years: | 6% |
| TTM: | 8% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 24% |
| 5 Years: | -10% |
| 3 Years: | 10% |
| TTM: | 107% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 15% |
| 5 Years: | 8% |
| 3 Years: | 48% |
| 1 Year: | 14% |
| Return on Equity | |
|---|---|
| 10 Years: | 10% |
| 5 Years: | 6% |
| 3 Years: | 1% |
| Last Year: | 10% |
Last Updated: September 5, 2025, 8:35 am
Balance Sheet
Last Updated: December 4, 2025, 1:30 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 15 | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 16 |
| Reserves | 2,611 | 2,438 | 2,951 | 3,420 | 4,071 | 4,793 | 5,588 | 4,726 | 5,303 | 5,383 | 5,418 | 6,239 | 6,576 |
| Borrowings | 4,395 | 4,793 | 4,493 | 4,045 | 3,469 | 4,840 | 4,808 | 2,830 | 3,192 | 3,677 | 3,664 | 2,731 | 2,883 |
| Other Liabilities | 1,842 | 1,372 | 1,280 | 1,417 | 1,902 | 1,670 | 1,898 | 1,192 | 1,319 | 1,853 | 2,240 | 3,598 | 4,047 |
| Total Liabilities | 8,864 | 8,619 | 8,740 | 8,899 | 9,457 | 11,319 | 12,310 | 8,763 | 9,830 | 10,929 | 11,338 | 12,584 | 13,521 |
| Fixed Assets | 5,099 | 4,911 | 5,104 | 5,107 | 5,401 | 5,648 | 6,340 | 4,609 | 4,871 | 5,183 | 5,091 | 5,176 | 7,354 |
| CWIP | 472 | 597 | 611 | 684 | 671 | 901 | 768 | 897 | 1,090 | 1,562 | 2,103 | 3,630 | 2,344 |
| Investments | 34 | 40 | 85 | 103 | 124 | 115 | 69 | 241 | 239 | 256 | 42 | 44 | 45 |
| Other Assets | 3,259 | 3,071 | 2,939 | 3,006 | 3,262 | 4,654 | 5,133 | 3,017 | 3,631 | 3,928 | 4,101 | 3,735 | 3,778 |
| Total Assets | 8,864 | 8,619 | 8,740 | 8,899 | 9,457 | 11,319 | 12,310 | 8,763 | 9,830 | 10,929 | 11,338 | 12,584 | 13,521 |
Below is a detailed analysis of the balance sheet data for Jubilant Pharmova Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 16.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 16.00 Cr..
- For Reserves, as of Sep 2025, the value is 6,576.00 Cr.. The value appears strong and on an upward trend. It has increased from 6,239.00 Cr. (Mar 2025) to 6,576.00 Cr., marking an increase of 337.00 Cr..
- For Borrowings, as of Sep 2025, the value is 2,883.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 2,731.00 Cr. (Mar 2025) to 2,883.00 Cr., marking an increase of 152.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 4,047.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 3,598.00 Cr. (Mar 2025) to 4,047.00 Cr., marking an increase of 449.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 13,521.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 12,584.00 Cr. (Mar 2025) to 13,521.00 Cr., marking an increase of 937.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 7,354.00 Cr.. The value appears strong and on an upward trend. It has increased from 5,176.00 Cr. (Mar 2025) to 7,354.00 Cr., marking an increase of 2,178.00 Cr..
- For CWIP, as of Sep 2025, the value is 2,344.00 Cr.. The value appears to be declining and may need further review. It has decreased from 3,630.00 Cr. (Mar 2025) to 2,344.00 Cr., marking a decrease of 1,286.00 Cr..
- For Investments, as of Sep 2025, the value is 45.00 Cr.. The value appears strong and on an upward trend. It has increased from 44.00 Cr. (Mar 2025) to 45.00 Cr., marking an increase of 1.00 Cr..
- For Other Assets, as of Sep 2025, the value is 3,778.00 Cr.. The value appears strong and on an upward trend. It has increased from 3,735.00 Cr. (Mar 2025) to 3,778.00 Cr., marking an increase of 43.00 Cr..
- For Total Assets, as of Sep 2025, the value is 13,521.00 Cr.. The value appears strong and on an upward trend. It has increased from 12,584.00 Cr. (Mar 2025) to 13,521.00 Cr., marking an increase of 937.00 Cr..
Notably, the Reserves (6,576.00 Cr.) exceed the Borrowings (2,883.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 995.00 | 606.00 | -3.00 | -3.00 | -2.00 | -3.00 | -3.00 | -1.00 | -2.00 | 776.00 | 898.00 | -1.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 51 | 52 | 60 | 63 | 55 | 51 | 79 | 49 | 55 | 56 | 50 | 45 |
| Inventory Days | 200 | 169 | 207 | 223 | 177 | 147 | 463 | 268 | 308 | 268 | 220 | 178 |
| Days Payable | 107 | 99 | 106 | 137 | 145 | 106 | 273 | 124 | 139 | 160 | 146 | 158 |
| Cash Conversion Cycle | 144 | 122 | 162 | 149 | 87 | 92 | 268 | 194 | 224 | 165 | 124 | 65 |
| Working Capital Days | -92 | 12 | 4 | 50 | 45 | 45 | 62 | 74 | 56 | 57 | 56 | 16 |
| ROCE % | 11% | 6% | 13% | 15% | 15% | 16% | 15% | 12% | 10% | 3% | 7% | 10% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Quant Small Cap Fund | 2,947,185 | 1.06 | 316.32 | N/A | N/A | N/A |
| Bandhan Small Cap Fund | 1,967,867 | 1.11 | 211.21 | 1,812,233 | 2026-01-26 08:21:04 | 8.59% |
| Kotak Multicap Fund | 1,873,926 | 0.87 | 201.13 | 1,842,613 | 2026-01-24 23:50:51 | 1.7% |
| Bandhan Focused Fund | 955,222 | 4.98 | 102.52 | 854,914 | 2026-01-26 02:18:51 | 11.73% |
| Kotak Special Opportunities Fund | 650,000 | 4.29 | 69.76 | N/A | N/A | N/A |
| Kotak Contra Fund | 578,400 | 1.21 | 62.08 | N/A | N/A | N/A |
| HDFC Manufacturing Fund | 500,000 | 0.49 | 53.67 | N/A | N/A | N/A |
| Aditya Birla Sun Life Small Cap Fund | 499,254 | 1.09 | 53.58 | 476,931 | 2026-01-25 15:08:02 | 4.68% |
| KotaK MNC Fund | 360,000 | 1.86 | 38.64 | N/A | N/A | N/A |
| HDFC Pharma and Healthcare Fund | 317,568 | 1.72 | 34.08 | N/A | N/A | N/A |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Basic EPS (Rs.) | 52.99 | 4.87 | -3.83 | 26.00 | 52.48 |
| Diluted EPS (Rs.) | 52.99 | 4.86 | -3.83 | 26.00 | 52.48 |
| Cash EPS (Rs.) | 76.29 | 27.25 | 29.98 | 50.55 | 73.70 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 395.88 | 343.11 | 338.91 | 333.97 | 297.85 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 395.88 | 343.11 | 338.91 | 333.97 | 297.85 |
| Revenue From Operations / Share (Rs.) | 457.88 | 424.23 | 394.85 | 385.08 | 383.10 |
| PBDIT / Share (Rs.) | 77.88 | 61.36 | 51.20 | 73.35 | 88.83 |
| PBIT / Share (Rs.) | 54.55 | 37.19 | 16.38 | 49.37 | 66.91 |
| PBT / Share (Rs.) | 62.09 | 9.27 | 0.97 | 40.23 | 54.01 |
| Net Profit / Share (Rs.) | 52.96 | 3.08 | -4.85 | 26.57 | 51.78 |
| NP After MI And SOA / Share (Rs.) | 53.13 | 4.88 | -3.83 | 26.00 | 52.51 |
| PBDIT Margin (%) | 17.00 | 14.46 | 12.96 | 19.04 | 23.18 |
| PBIT Margin (%) | 11.91 | 8.76 | 4.14 | 12.82 | 17.46 |
| PBT Margin (%) | 13.56 | 2.18 | 0.24 | 10.44 | 14.09 |
| Net Profit Margin (%) | 11.56 | 0.72 | -1.22 | 6.90 | 13.51 |
| NP After MI And SOA Margin (%) | 11.60 | 1.15 | -0.97 | 6.75 | 13.70 |
| Return on Networth / Equity (%) | 13.41 | 1.41 | -1.12 | 7.78 | 17.62 |
| Return on Capital Employeed (%) | 8.13 | 6.08 | 2.77 | 9.35 | 13.53 |
| Return On Assets (%) | 6.58 | 0.66 | -0.54 | 4.14 | 9.37 |
| Long Term Debt / Equity (X) | 0.34 | 0.58 | 0.57 | 0.46 | 0.54 |
| Total Debt / Equity (X) | 0.38 | 0.62 | 0.63 | 0.55 | 0.54 |
| Asset Turnover Ratio (%) | 0.59 | 0.59 | 0.59 | 0.01 | 0.37 |
| Current Ratio (X) | 1.65 | 2.05 | 2.12 | 2.20 | 2.81 |
| Quick Ratio (X) | 1.13 | 1.37 | 1.34 | 1.42 | 1.74 |
| Inventory Turnover Ratio (X) | 5.98 | 1.36 | 1.26 | 0.00 | 1.44 |
| Dividend Payout Ratio (NP) (%) | 9.48 | 103.24 | -130.60 | 19.23 | 0.00 |
| Dividend Payout Ratio (CP) (%) | 6.58 | 17.34 | 16.15 | 10.00 | 0.00 |
| Earning Retention Ratio (%) | 90.52 | -3.24 | 230.60 | 80.77 | 0.00 |
| Cash Earning Retention Ratio (%) | 93.42 | 82.66 | 83.85 | 90.00 | 0.00 |
| Interest Coverage Ratio (X) | 5.12 | 3.56 | 4.33 | 8.03 | 7.68 |
| Interest Coverage Ratio (Post Tax) (X) | 2.99 | 1.80 | 0.89 | 3.91 | 4.17 |
| Enterprise Value (Cr.) | 15436.46 | 11426.80 | 6827.69 | 8114.60 | 12743.97 |
| EV / Net Operating Revenue (X) | 2.13 | 1.70 | 1.09 | 1.32 | 2.09 |
| EV / EBITDA (X) | 12.54 | 11.79 | 8.38 | 6.95 | 9.01 |
| MarketCap / Net Operating Revenue (X) | 1.95 | 1.34 | 0.70 | 1.01 | 1.78 |
| Retention Ratios (%) | 90.51 | -3.24 | 230.60 | 80.76 | 0.00 |
| Price / BV (X) | 2.25 | 1.65 | 0.82 | 1.16 | 2.28 |
| Price / Net Operating Revenue (X) | 1.95 | 1.34 | 0.70 | 1.01 | 1.78 |
| EarningsYield | 0.05 | 0.01 | -0.01 | 0.06 | 0.07 |
After reviewing the key financial ratios for Jubilant Pharmova Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 52.99. This value is within the healthy range. It has increased from 4.87 (Mar 24) to 52.99, marking an increase of 48.12.
- For Diluted EPS (Rs.), as of Mar 25, the value is 52.99. This value is within the healthy range. It has increased from 4.86 (Mar 24) to 52.99, marking an increase of 48.13.
- For Cash EPS (Rs.), as of Mar 25, the value is 76.29. This value is within the healthy range. It has increased from 27.25 (Mar 24) to 76.29, marking an increase of 49.04.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 395.88. It has increased from 343.11 (Mar 24) to 395.88, marking an increase of 52.77.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 395.88. It has increased from 343.11 (Mar 24) to 395.88, marking an increase of 52.77.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 457.88. It has increased from 424.23 (Mar 24) to 457.88, marking an increase of 33.65.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 77.88. This value is within the healthy range. It has increased from 61.36 (Mar 24) to 77.88, marking an increase of 16.52.
- For PBIT / Share (Rs.), as of Mar 25, the value is 54.55. This value is within the healthy range. It has increased from 37.19 (Mar 24) to 54.55, marking an increase of 17.36.
- For PBT / Share (Rs.), as of Mar 25, the value is 62.09. This value is within the healthy range. It has increased from 9.27 (Mar 24) to 62.09, marking an increase of 52.82.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 52.96. This value is within the healthy range. It has increased from 3.08 (Mar 24) to 52.96, marking an increase of 49.88.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 53.13. This value is within the healthy range. It has increased from 4.88 (Mar 24) to 53.13, marking an increase of 48.25.
- For PBDIT Margin (%), as of Mar 25, the value is 17.00. This value is within the healthy range. It has increased from 14.46 (Mar 24) to 17.00, marking an increase of 2.54.
- For PBIT Margin (%), as of Mar 25, the value is 11.91. This value is within the healthy range. It has increased from 8.76 (Mar 24) to 11.91, marking an increase of 3.15.
- For PBT Margin (%), as of Mar 25, the value is 13.56. This value is within the healthy range. It has increased from 2.18 (Mar 24) to 13.56, marking an increase of 11.38.
- For Net Profit Margin (%), as of Mar 25, the value is 11.56. This value exceeds the healthy maximum of 10. It has increased from 0.72 (Mar 24) to 11.56, marking an increase of 10.84.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 11.60. This value is within the healthy range. It has increased from 1.15 (Mar 24) to 11.60, marking an increase of 10.45.
- For Return on Networth / Equity (%), as of Mar 25, the value is 13.41. This value is below the healthy minimum of 15. It has increased from 1.41 (Mar 24) to 13.41, marking an increase of 12.00.
- For Return on Capital Employeed (%), as of Mar 25, the value is 8.13. This value is below the healthy minimum of 10. It has increased from 6.08 (Mar 24) to 8.13, marking an increase of 2.05.
- For Return On Assets (%), as of Mar 25, the value is 6.58. This value is within the healthy range. It has increased from 0.66 (Mar 24) to 6.58, marking an increase of 5.92.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.34. This value is within the healthy range. It has decreased from 0.58 (Mar 24) to 0.34, marking a decrease of 0.24.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.38. This value is within the healthy range. It has decreased from 0.62 (Mar 24) to 0.38, marking a decrease of 0.24.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.59. There is no change compared to the previous period (Mar 24) which recorded 0.59.
- For Current Ratio (X), as of Mar 25, the value is 1.65. This value is within the healthy range. It has decreased from 2.05 (Mar 24) to 1.65, marking a decrease of 0.40.
- For Quick Ratio (X), as of Mar 25, the value is 1.13. This value is within the healthy range. It has decreased from 1.37 (Mar 24) to 1.13, marking a decrease of 0.24.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 5.98. This value is within the healthy range. It has increased from 1.36 (Mar 24) to 5.98, marking an increase of 4.62.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 9.48. This value is below the healthy minimum of 20. It has decreased from 103.24 (Mar 24) to 9.48, marking a decrease of 93.76.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 6.58. This value is below the healthy minimum of 20. It has decreased from 17.34 (Mar 24) to 6.58, marking a decrease of 10.76.
- For Earning Retention Ratio (%), as of Mar 25, the value is 90.52. This value exceeds the healthy maximum of 70. It has increased from -3.24 (Mar 24) to 90.52, marking an increase of 93.76.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 93.42. This value exceeds the healthy maximum of 70. It has increased from 82.66 (Mar 24) to 93.42, marking an increase of 10.76.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 5.12. This value is within the healthy range. It has increased from 3.56 (Mar 24) to 5.12, marking an increase of 1.56.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 2.99. This value is below the healthy minimum of 3. It has increased from 1.80 (Mar 24) to 2.99, marking an increase of 1.19.
- For Enterprise Value (Cr.), as of Mar 25, the value is 15,436.46. It has increased from 11,426.80 (Mar 24) to 15,436.46, marking an increase of 4,009.66.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 2.13. This value is within the healthy range. It has increased from 1.70 (Mar 24) to 2.13, marking an increase of 0.43.
- For EV / EBITDA (X), as of Mar 25, the value is 12.54. This value is within the healthy range. It has increased from 11.79 (Mar 24) to 12.54, marking an increase of 0.75.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.95. This value is within the healthy range. It has increased from 1.34 (Mar 24) to 1.95, marking an increase of 0.61.
- For Retention Ratios (%), as of Mar 25, the value is 90.51. This value exceeds the healthy maximum of 70. It has increased from -3.24 (Mar 24) to 90.51, marking an increase of 93.75.
- For Price / BV (X), as of Mar 25, the value is 2.25. This value is within the healthy range. It has increased from 1.65 (Mar 24) to 2.25, marking an increase of 0.60.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.95. This value is within the healthy range. It has increased from 1.34 (Mar 24) to 1.95, marking an increase of 0.61.
- For EarningsYield, as of Mar 25, the value is 0.05. This value is below the healthy minimum of 5. It has increased from 0.01 (Mar 24) to 0.05, marking an increase of 0.04.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Jubilant Pharmova Ltd:
- Net Profit Margin: 11.56%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 8.13% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 13.41% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 2.99
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.13
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 32.5 (Industry average Stock P/E: 54.25)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.38
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 11.56%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Bhartiagram, Amroha District Uttar Pradesh 244223 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Shyam S Bhartia | Chairman |
| Mr. Hari S Bhartia | Co-Chairman |
| Mr. Priyavrat Bhartia | Managing Director |
| Mr. Arjun Shanker Bhartia | Joint Managing Director |
| Mr. Arvind Chokhany | WholeTime Director & Group CFO |
| Dr. Ramakrishnan Arul | Whole Time Director |
| Dr. Harsh Mahajan | Independent Director |
| Mr. Arun Seth | Independent Director |
| Mr. Vivek Mehra | Independent Director |
| Ms. Shivpriya Nanda | Independent Director |
| Mr. Shirish G Belapure | Independent Director |
| Mr. Sushil Kumar Roongta | Independent Director |
FAQ
What is the intrinsic value of Jubilant Pharmova Ltd?
Jubilant Pharmova Ltd's intrinsic value (as of 13 February 2026) is ₹1063.44 which is 12.77% higher the current market price of ₹943.00, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's ₹15,010 Cr. market cap, FY2025-2026 high/low of ₹1,250/802, reserves of ₹6,576 Cr, and liabilities of ₹13,521 Cr.
What is the Market Cap of Jubilant Pharmova Ltd?
The Market Cap of Jubilant Pharmova Ltd is 15,010 Cr..
What is the current Stock Price of Jubilant Pharmova Ltd as on 13 February 2026?
The current stock price of Jubilant Pharmova Ltd as on 13 February 2026 is ₹943.
What is the High / Low of Jubilant Pharmova Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Jubilant Pharmova Ltd stocks is ₹1,250/802.
What is the Stock P/E of Jubilant Pharmova Ltd?
The Stock P/E of Jubilant Pharmova Ltd is 32.5.
What is the Book Value of Jubilant Pharmova Ltd?
The Book Value of Jubilant Pharmova Ltd is 414.
What is the Dividend Yield of Jubilant Pharmova Ltd?
The Dividend Yield of Jubilant Pharmova Ltd is 0.53 %.
What is the ROCE of Jubilant Pharmova Ltd?
The ROCE of Jubilant Pharmova Ltd is 9.54 %.
What is the ROE of Jubilant Pharmova Ltd?
The ROE of Jubilant Pharmova Ltd is 9.55 %.
What is the Face Value of Jubilant Pharmova Ltd?
The Face Value of Jubilant Pharmova Ltd is 1.00.